 HAMPTON, N.J., Sept. 23, 2021 GLOBE NEWSWIRE -- Celldex Therapeutics, Inc. NASDAQ:CLDX today announced that an abstract describing symptom control and quality of life measurements from the Phase 1b study of CDX-0159 in patients with antihistamine refractory cold contact urticaria ColdU and symptomatic dermographism SD, the two most common forms of chronic inducible urticaria CIndU, has been accepted as an electronic poster with voice over at the European Academy of Dermatology and Venereology EADV 30th Congress being held virtually September 29 - October 2, 2021. 